**HIGHLIGHTS OF PRESCRIBING INFORMATION**
These highlights do not include all the information needed to use FINTEPLA safely and effectively. See full prescribing information for FINTEPLA.

FINTEPLA® (fenfluramine) oral solution, CIV
Initial U.S. Approval: 1973

**WARNING: VALVULAR HEART DISEASE and PULMONARY ARTERIAL HYPERTENSION**
See full prescribing information for complete boxed warning.
- There is an association between serotonergic drugs with 5-HT2B receptor agonist activity, including fenfluramine (the active ingredient in FINTEPLA), and valvular heart disease and pulmonary arterial hypertension. (5.1)
- Echocardiogram assessments are required before, during, and after treatment with FINTEPLA. (2.1, 2.5, 5.1)
- FINTEPLA is available only through a restricted program called the FINTEPLA REMS. (5.2)

**RECENT MAJOR CHANGES**
- Indications and Usage (1) 3/2022
- Dosage and Administration (2.2, 2.3, 24) 3/2022
- Warnings and Precautions (5.1, 5.3, 5.4, 5.8) 3/2022

**INDICATIONS AND USAGE**
FINTEPLA is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut Syndrome in patients 2 years of age and older. (1)

**DOSE AND ADMINISTRATION**
- FINTEPLA is to be administered orally and may be taken with or without food. (2.2)
- Dravet Syndrome
  - The initial starting and maintenance dosage is 0.1 mg/kg twice daily, which can be increased weekly based on efficacy and tolerability. (2.2)
  - Patients not on concomitant stiripentol: The maximum daily maintenance dosage of FINTEPLA is 0.35 mg/kg twice daily (maximum daily dosage of 26 mg). (2.2)
  - Patients taking concomitant stiripentol plus clobazam: The maximum daily maintenance dosage of FINTEPLA for patients taking these medications is 0.2 mg/kg twice daily (maximum daily dosage of 17 mg). (2.2)
- Lennox-Gastaut Syndrome
  - The initial starting dosage is 0.1 mg/kg twice daily, which should be increased weekly based on tolerability. (2.2)
  - Patients not on concomitant stiripentol: The recommended maintenance dosage of FINTEPLA is 0.35 mg/kg twice daily (maximum daily dosage of 26 mg). (2.2)
  - Patients taking concomitant stiripentol plus clobazam: the recommended maintenance dosage is 0.2 mg/kg twice daily (maximum daily dosage of 17 mg). (2.2)
- Dosage modification is recommended in patients with severe renal impairment (2.4, 8.6)

**DOSE FORMS AND STRENGTHS**
Oral solution: 2.2 mg/mL fenfluramine (3)

**CONTRAINDICATIONS**
- Hypersensitivity to fenfluramine or any of the excipients in FINTEPLA (4)
- Within 14 days of the administration of monoamine oxidase inhibitors due to an increased risk of serotonin syndrome (4)

**WARNINGS AND PRECAUTIONS**
- Decreased Appetite and Decreased Weight: Advise patients that FINTEPLA can cause decreased appetite and decreased weight. (5.3)
- Somnolence, Sedation, and Lethargy: Monitor for somnolence and sedation. Advise patients not to drive or operate machinery until they have gained sufficient experience on FINTEPLA. (5.4)
- Suicidal Behavior and Ideation: Monitor patients for suicidal behavior and thoughts. (5.5)
- Withdrawal of Antiepileptic Drugs: FINTEPLA should be gradually withdrawn to minimize the risk of increased seizure frequency and status epilepticus. (5.6)
- Serotonin Syndrome: Advise patients that serotonin syndrome is a potentially life-threatening condition and may occur with FINTEPLA, particularly with concomitant administration of FINTEPLA with other serotonergic drugs. (5.7)
- Increase in Blood Pressure: Monitor blood pressure during treatment. (5.8)
- Glaucoma: Discontinue therapy in patients with acute decrease in visual acuity or ocular pain. (5.9)

**ADVERSE REACTIONS**
The most common adverse reactions (incidence at least 10% and greater than placebo) in patients with Dravet Syndrome were decreased appetite; somnolence, sedation, lethargy; diarrhea; constipation; abnormal echocardiogram; fatigue, malaise, asthenia; ataxia, balance disorder, gait disturbance; blood pressure increased; drooling, salivary hypersecretion; pyrexia; upper respiratory tract infection; vomiting; decreased weight; fall; status epilepticus. (6.1)

The most common adverse reactions (incidence at least 10% and greater than placebo) in patients with Lennox-Gastaut Syndrome were decreased appetite; somnolence, sedation, lethargy; diarrhea; constipation; abnormal echocardiogram; fatigue, malaise, asthenia; ataxia, balance disorder, gait disturbance; blood pressure increased; drooling, salivary hypersecretion; pyrexia; upper respiratory tract infection; vomiting; decreased weight; fall; status epilepticus. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Zogenix Inc. at 1-866-964-3649 (1-866-Zogenix) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

**DRUG INTERACTIONS**
- Dose adjustment is required for patients taking stiripentol plus clobazam. (2.2, 2.3, 7.1)
- Strong CYP1A2, CYP2B6, or CYP3A4 inducers: it is recommended to avoid coadministration with FINTEPLA. If coadministration is necessary, consider a FINTEPLA dosage increase. (7.1)
- Strong CYP1A2 or CYP2D6 inhibitors: consider a FINTEPLA dose adjustment. (2.3, 7.1)

**USE IN SPECIFIC POPULATIONS**
- Pregnancy: Based on animal data, may cause fetal harm (8.1)
- Administration to patients with hepatic impairment is not recommended. (8.7)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 6/2022
FULL PRESCRIBING INFORMATION: CONTENTS*
WARNING: VALVULAR HEART DISEASE and PULMONARY ARTERIAL HYPERTENSION

1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
   2.1 Assessments Prior to Initiating FINTEPLA
   2.2 Dosing Information
   2.3 Dosage Modifications for Patients with Concomitant Use of Strong CYP1A2 or CYP2D6 Inhibitors (DS and LGS)
   2.4 Dosage Modifications for Patients with Severe Renal Impairment (DS and LGS)
   2.5 Assessments During and After Administration of FINTEPLA
   2.6 Administration Instructions
   2.7 Discontinuation of FINTEPLA
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
   5.1 Valvular Heart Disease and Pulmonary Arterial Hypertension
   5.2 FINTEPLA REMS Program
   5.3 Decreased Appetite and Decreased Weight
   5.4 Somnolence, Sedation, and Lethargy
   5.5 Suicidal Behavior and Ideation
   5.6 Withdrawal of Antiepileptic Drugs
   5.7 Serotonin Syndrome
   5.8 Increase in Blood Pressure
   5.9 Glaucoma
6 ADVERSE REACTIONS
   6.1 Clinical Trials Experience
7 DRUG INTERACTIONS
   7.1 Effect of Other Drugs on FINTEPLA
   7.2 Effects of Serotonin Receptor Antagonists
   7.3 Serotonergic Drugs
8 USE IN SPECIFIC POPULATIONS
   8.1 Pregnancy
   8.2 Lactation
   8.3 Females and Males of Reproductive Potential
   8.4 Pediatric Use
   8.5 Geriatric Use
   8.6 Renal Impairment
   8.7 Hepatic Impairment
9 DRUG ABUSE AND DEPENDENCE
   9.1 Controlled Substance
10 OVERDOSAGE
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
   12.1 Mechanism of Action
   12.2 Pharmacodynamics
   12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY
14 CLINICAL STUDIES
   14.1 Dravet Syndrome
   14.2 Lennox-Gastaut Syndrome
16 HOW SUPPLIED/STORAGE AND HANDLING
   16.1 How Supplied
   16.2 Storage and Handling
17 PATIENT COUNSELING INFORMATION
*Sections or subsections omitted from the full prescribing information are not listed.
FULL PRESCRIBING INFORMATION

WARNING: VALVULAR HEART DISEASE and PULMONARY ARTERIAL HYPERTENSION

There is an association between serotonergic drugs with 5-HT2B receptor agonist activity, including fenfluramine (the active ingredient in FINTEPLA), and valvular heart disease and pulmonary arterial hypertension [see Warnings and Precautions (5.1)].

Echocardiogram assessments are required before, during, and after treatment with FINTEPLA. The benefits versus the risks of initiating or continuing FINTEPLA must be considered, based on echocardiogram findings [see Dosage and Administration (2.1, 2.5) and Warnings and Precautions (5.1)].

Because of the risks of valvular heart disease and pulmonary arterial hypertension, FINTEPLA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the FINTEPLA REMS [see Warnings and Precautions (5.2)].

1 INDICATIONS AND USAGE

FINTEPLA is indicated for the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.

2 DOSAGE AND ADMINISTRATION

2.1 Assessments Prior to Initiating FINTEPLA

Prior to starting treatment with FINTEPLA, obtain an echocardiogram assessment to evaluate for valvular heart disease and pulmonary arterial hypertension [see Dosage and Administration (2.5) and Warnings and Precautions (5.1)].

2.2 Dosing Information

FINTEPLA is to be administered orally and may be taken with or without food.

Dravet Syndrome

- The initial starting and maintenance dosage for patients with Dravet Syndrome is 0.1 mg/kg twice daily, which can be increased weekly based on efficacy and tolerability. Table 1 provides the recommended titration schedule, if needed.
- Patients with Dravet Syndrome not on concomitant stiripentol who are tolerating FINTEPLA at 0.1 mg/kg twice daily and require further reduction of seizures may benefit from a dosage increase up to a maximum recommended maintenance dosage of 0.35 mg/kg twice daily (maximum daily dosage of 26 mg).
- Patients with Dravet Syndrome taking concomitant stiripentol plus clobazam who are tolerating FINTEPLA at 0.1 mg/kg twice daily and require further reduction of seizures...
may benefit from a dosage increase up to a maximum recommended maintenance dosage of 0.2 mg/kg twice daily (maximum daily dosage of 17 mg) [see Drug Interactions (7.1)].

**Lennox-Gastaut Syndrome**

- The initial starting dosage for patients with Lennox-Gastaut syndrome is 0.1 mg/kg twice daily, which should be increased weekly based on tolerability. Table 1 provides the recommended titration schedule.
- Patients with Lennox-Gastaut syndrome not on concomitant stiripentol who are tolerating FINTEPLA should be titrated to the recommended maintenance dosage of 0.35 mg/kg twice daily (maximum daily dosage of 26 mg).
- Patients with Lennox-Gastaut syndrome taking concomitant stiripentol plus clobazam who are tolerating FINTEPLA should be titrated to the recommended maintenance dosage of 0.2 mg/kg twice daily (maximum daily dosage of 17 mg) [see Drug Interactions (7.1)].

**Table 1: FINTEPLA Recommended Titration Schedule**

<table>
<thead>
<tr>
<th></th>
<th>Without concomitant stiripentol*</th>
<th>With concomitant stiripentol plus clobazam</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Weight-based Dosage</strong></td>
<td>Maximum Total Daily Dosage±</td>
<td>Weight-based Dosage</td>
</tr>
<tr>
<td>Initial Dosage+</td>
<td>0.1 mg/kg twice daily</td>
<td>26 mg</td>
</tr>
<tr>
<td>Day 7</td>
<td>0.2 mg/kg twice daily</td>
<td>26 mg</td>
</tr>
<tr>
<td>Day 14**</td>
<td>0.35 mg/kg twice daily</td>
<td>26 mg</td>
</tr>
</tbody>
</table>

* For patients not on concomitant stiripentol in whom a more rapid titration is warranted, the dose may be increased every 4 days.
+ For patients with Dravet Syndrome, dosage may be increased based on clinical response to the maximum recommended dosage, as needed.
** For patients with Lennox-Gastaut syndrome, dosage should be increased as tolerated to the recommended maintenance dosage (i.e., Day 14).
± For maximum dosage with concomitant use of strong CYP1A2 or CYP2D6 inhibitors or in patients with severe renal impairment see Dosage and Administration 2.3, 2.4.

**2.3 Dosage Modifications for Patients with Concomitant Use of Strong CYP1A2 or CYP2D6 Inhibitors (DS and LGS)**

For patients with concomitant use of FINTEPLA with a strong CYP1A2 or CYP2D6 inhibitor, a maximum total daily dosage of 20 mg without concomitant stiripentol and 17 mg with concomitant stiripentol plus clobazam is recommended. [see Drug Interactions (7.1)].
2.4 Dosage Modifications for Patients with Severe Renal Impairment (DS and LGS)
For patients with severe renal impairment (estimated glomerular filtration rate (eGFR) 15 to 29 mL/min/1.73m²), a maximum total daily dosage of 20 mg without concomitant stiripentol and 17 mg with concomitant stiripentol plus clobazam is recommended [see Use in Specific Populations (8.6)].

2.5 Assessments During and After Administration of FINTEPLA
To evaluate for valvular heart disease and pulmonary arterial hypertension, obtain an echocardiogram assessment every 6 months during treatment with FINTEPLA, and 3 to 6 months after the final dose of FINTEPLA [see Warnings and Precautions (5.1)].

2.6 Administration Instructions
A calibrated measuring device (either a 3 mL or 6 mL oral syringe) will be provided by the pharmacy and is recommended to measure and administer the prescribed dose accurately [see How Supplied/Storage and Handling (16.1)]. A household teaspoon or tablespoon is not an adequate measuring device and should not be used.

Discard any unused FINTEPLA oral solution remaining after 3 months of first opening the bottle or the “Discard After” date on the bottle, whichever is sooner.

FINTEPLA is compatible with commercially available gastric and nasogastric feeding tubes.

2.7 Discontinuation of FINTEPLA
When discontinuing FINTEPLA, the dose should be decreased gradually. As with all antiepileptic drugs, abrupt discontinuation should be avoided when possible to minimize the risk of increased seizure frequency and status epilepticus [see Warnings and Precautions (5.6)].

3 DOSAGE FORMS AND STRENGTHS
Oral solution: 2.2 mg/mL fenfluramine as a clear, colorless, cherry flavored liquid.

4 CONTRAINDICATIONS
FINTEPLA is contraindicated in patients with:

- Hypersensitivity to fenfluramine or any of the excipients in FINTEPLA [see Description (11)]
- Concomitant use, or within 14 days of the administration, of monoamine oxidase inhibitors because of an increased risk of serotonin syndrome [see Warnings and Precautions (5.7)]

5 WARNINGS AND PRECAUTIONS

5.1 Valvular Heart Disease and Pulmonary Arterial Hypertension
Because of the association between serotonergic drugs with 5-HT2B receptor agonist activity, including fenfluramine (the active ingredient in FINTEPLA), and valvular heart disease (VHD) and pulmonary arterial hypertension (PAH), cardiac monitoring is required prior to starting
treatment, during treatment, and after treatment with FINTEPLA concludes. Cardiac monitoring via echocardiogram can identify evidence of valvular heart disease and pulmonary arterial hypertension prior to a patient becoming symptomatic, aiding in early detection of these conditions. In clinical trials for DS and LGS of up to 3 years in duration, no patient receiving FINTEPLA developed valvular heart disease or pulmonary arterial hypertension [see Boxed Warning and Adverse Reactions (6.1)].

Monitoring

Prior to starting treatment, patients must undergo an echocardiogram to evaluate for valvular heart disease and pulmonary arterial hypertension.

Echocardiograms should be repeated every 6 months, and once 3-6 months post-treatment with FINTEPLA.

The prescriber must consider the benefits versus the risks of initiating or continuing treatment with FINTEPLA if any of the following signs are observed via ECHO:

- Valvular abnormality or new abnormality via echocardiogram.
- VHD as indicated by mild or greater aortic regurgitation or moderate or greater mitral regurgitation, with additional characteristics of VHD (e.g., valve thickening or restrictive valve motion).
- PAH as indicated by elevated right heart/pulmonary artery pressure (PASP > 35 mm Hg).

FINTEPLA is available only through a restricted program under a REMS [see Warnings and Precautions (5.2)].

5.2 FINTEPLA REMS Program

FINTEPLA is available only through a restricted distribution program called the FINTEPLA REMS program because of the risk of valvular heart disease and pulmonary arterial hypertension [see Warnings and Precautions (5.1)].

Notable requirements of the FINTEPLA REMS Program include:

- Prescribers must be certified by enrolling in the FINTEPLA REMS program.
- Prescribers must counsel patients receiving FINTEPLA about the risk of valvular heart disease and pulmonary arterial hypertension, how to recognize signs and symptoms of valvular heart disease and pulmonary arterial hypertension, the need for baseline (pretreatment) and periodic cardiac monitoring via echocardiogram during FINTEPLA treatment, and cardiac monitoring after FINTEPLA treatment.
- Patients must enroll in the REMS program and comply with ongoing monitoring requirements [see Warnings and Precautions (5.1)].
- The pharmacy must be certified by enrolling in the REMS program and must only dispense to patients who are authorized to receive FINTEPLA.
- Wholesalers and distributors must only distribute to certified pharmacies.

Further information is available at www.FinteplaREMS.com or by telephone at 1-877-964-3649.
5.3 Decreased Appetite and Decreased Weight

FINTEPLA can cause decreases in appetite and weight. In placebo-controlled studies for DS (Study 1 and Study 2 combined), approximately 37% of patients treated with FINTEPLA reported, as an adverse reaction, decreased appetite and approximately 9% reported decreased weight, as compared to 8% and 1%, respectively, of patients on placebo. In the placebo-controlled study for LGS (Study 3), approximately 28% of patients treated with FINTEPLA reported, as an adverse reaction, decreased appetite and approximately 5% reported decreased weight, as compared to 15% and 2%, respectively, of patients on placebo [see Adverse Reactions (6.1)]. By the end of the controlled studies, 19% (Studies 1 and 2 combined) of DS patients and 7% (Study 3) of LGS patients treated with FINTEPLA had a measured decrease in weight of 7% or greater from their baseline weight, compared to 2% (Study 1 and 2) and 0% (Study 3) of patients on placebo. This measured decrease in weight appeared to be dose-related. In the controlled studies for DS, 26% of patients on FINTEPLA 0.7 mg/kg/day (Study 1), 19% of patients on FINTEPLA 0.4 mg/kg/day in combination with stiripentol (Study 2), and 13% of patients taking FINTEPLA 0.2 mg/kg/day (Study 1) experienced at least a 7% decrease in weight from baseline. In the controlled study for LGS, 9% of patients on FINTEPLA 0.7 mg/kg/day (Study 3) and 6% of patients on FINTEPLA 0.2 mg/kg/day (Study 3) experienced at least a 7% decrease in weight from baseline. Approximately half of the patients with LGS and most patients with DS resumed the expected measured increases in weight during the open-label extension studies. Given the frequency of these adverse reactions, the growth of pediatric patients treated with FINTEPLA should be carefully monitored. Weight should be monitored regularly during treatment with FINTEPLA, and dose modifications should be considered if a decrease in weight is observed.

5.4 Somnolence, Sedation, and Lethargy

FINTEPLA can cause somnolence, sedation, and lethargy. In controlled studies for DS (Study 1 and Study 2 combined), the incidence of somnolence, sedation, and lethargy was 25% in patients treated with FINTEPLA, compared with 11% of patients on placebo. In the controlled study for LGS (Study 3), the incidence of somnolence, sedation, and lethargy was 19% in patients treated with FINTEPLA, compared with 16% of patients on placebo. In general, these effects may diminish with continued treatment [see Adverse Reactions (6.1)].

Other central nervous system (CNS) depressants, including alcohol, could potentiate these effects of FINTEPLA. Prescribers should monitor patients for somnolence and sedation and should advise patients not to drive or operate machinery until they have gained sufficient experience on FINTEPLA to gauge whether it adversely affects their ability to drive or operate machinery.

5.5 Suicidal Behavior and Ideation

Antiepileptic drugs (AEDs), including FINTEPLA, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with an AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, or any unusual changes in mood or behavior.

Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs that did not include FINTEPLA showed that patients randomized to one of
the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide.

The increased risk of suicidal thoughts or behavior with AEDs was observed as early as 1 week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.

The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5-100 years) in the clinical trials analyzed. Table 2 shows absolute and relative risk by indication for all evaluated AEDs.

### Table 2: Risk of Suicidal Thoughts or Behaviors by Indication for Antiepileptic Drugs in the Pooled Analysis

<table>
<thead>
<tr>
<th>Indication</th>
<th>Placebo Patients with Events per 1000 Patients</th>
<th>Drug Patients with Events per 1000 Patients</th>
<th>Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients</th>
<th>Risk Difference: Additional Drug Patients with Events per 1000 Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epilepsy</td>
<td>1.0</td>
<td>3.4</td>
<td>3.5</td>
<td>2.4</td>
</tr>
<tr>
<td>Psychiatric</td>
<td>5.7</td>
<td>8.5</td>
<td>1.5</td>
<td>2.9</td>
</tr>
<tr>
<td>Other</td>
<td>1.0</td>
<td>1.8</td>
<td>1.9</td>
<td>0.9</td>
</tr>
<tr>
<td>Total</td>
<td>2.4</td>
<td>4.3</td>
<td>1.8</td>
<td>1.9</td>
</tr>
</tbody>
</table>

The relative risk for suicidal thoughts or behavior was higher in clinical trials in patients with epilepsy than in clinical trials in patients with psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications.

Anyone considering prescribing FINTEPLA or any other AED must balance the risk of suicidal thoughts or behaviors with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.

5.6 **Withdrawal of Antiepileptic Drugs**

As with most AEDs, FINTEPLA should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus. If withdrawal is needed because of a serious adverse reaction, rapid discontinuation can be considered.
5.7 Serotonin Syndrome

Serotonin syndrome, a potentially life-threatening condition, may occur with FINTEPLA, particularly with concomitant administration of FINTEPLA with other serotonergic drugs, including, but not limited to, selective serotonin-norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), bupropion, triptans, dietary supplements (e.g., St. John’s Wort, tryptophan), drugs that impair metabolism of serotonin (including monoamine oxidase inhibitors [MAOIs], which are contraindicated with FINTEPLA [see Contraindications (4)], dextromethorphan, lithium, tramadol, and antipsychotics with serotonergic agonist activity. Patients should be monitored for the emergence of signs and symptoms of serotonin syndrome, which include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular signs (e.g., hyperreflexia, incoordination), and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). If serotonin syndrome is suspected, treatment with FINTEPLA should be stopped immediately and symptomatic treatment should be started.

5.8 Increase in Blood Pressure

FINTEPLA can cause an increase in blood pressure [see Adverse Reactions (6.1)]. Rare cases of significant elevation in blood pressure, including hypertensive crisis, has been reported in adult patients treated with fenfluramine, including patients without a history of hypertension. In clinical trials of up to 3 years in duration, no pediatric or adult patient receiving FINTEPLA developed a hypertensive crisis. Monitor blood pressure in patients treated with FINTEPLA.

5.9 Glaucoma

Fenfluramine can cause mydriasis and can precipitate angle closure glaucoma. Consider discontinuing treatment with FINTEPLA in patients with acute decreases in visual acuity or ocular pain.

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in labeling:

- Valvular Heart Disease and Pulmonary Arterial Hypertension [see Warnings and Precautions (5.1)]
- Decreased Appetite and Decreased Weight [see Warnings and Precautions (5.3)]
- Somnolence, Sedation, and Lethargy [see Warnings and Precautions (5.4)]
- Suicidal Behavior and Ideation [see Warnings and Precautions (5.5)]
- Withdrawal of Antiepileptic Drugs [see Warnings and Precautions (5.6)]
- Serotonin Syndrome [see Warnings and Precautions (5.7)]
- Increase in Blood Pressure [see Warnings and Precautions (5.8)]
- Glaucoma [see Warnings and Precautions (5.9)]
6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In controlled and uncontrolled trials in patients with Dravet syndrome (DS), 341 patients were treated with FINTEPLA, including 312 patients treated for more than 6 months, 284 patients treated for more than 1 year, and 138 patients treated for more than 2 years.

In controlled and uncontrolled trials in patients with Lennox-Gastaut syndrome (LGS), 262 patients were treated with FINTEPLA, including 219 patients treated for more than 6 months, 172 patients treated for more than 1 year, and 127 patients treated for more than 2 years.

Dravet Syndrome

In placebo-controlled trials of patients with DS taking concomitant standard of care AEDs, 122 patients were treated with FINTEPLA and 84 patients received placebo [see Clinical Studies (14.1)]. The duration of treatment in these trials was 16 weeks (Study 1) or 17 weeks (Study 2). In Study 1 and Study 2, the mean age was 9 years (range 2 to 19 years) and approximately 46% of patients were female and 74% were White. All patients were receiving at least one other AED.

In Study 1 and Study 2, the rates of discontinuation as a result of any adverse reaction were 13%, 0%, and 7% for patients treated with FINTEPLA 0.7 mg/kg/day, 0.2 mg/kg/day, and 0.4 mg/kg/day in combination with stiripentol, respectively, compared to 6% for patients on placebo. The most frequent adverse reaction leading to discontinuation in the patients treated with any dose of FINTEPLA was somnolence (3%).

The most common adverse reactions that occurred in patients treated with FINTEPLA (incidence at least 10% and greater than placebo) were decreased appetite; somnolence, sedation, lethargy; diarrhea; constipation; abnormal echocardiogram; fatigue, malaise, asthenia; ataxia, balance disorder, gait disturbance; blood pressure increased; drooling, salivary hypersecretion; pyrexia; upper respiratory tract infection; vomiting; decreased weight; fall; status epilepticus.

Table 3 lists the adverse reactions that were reported in 5% or more of patients treated with FINTEPLA and at a rate greater than those on placebo during the titration and maintenance phases of Study 1 and Study 2.

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>FINTEPLA Dose Group</th>
<th>Combined Placebo Group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Study 1</td>
<td>Study 2</td>
</tr>
<tr>
<td></td>
<td>0.2 mg/kg/day</td>
<td>0.7 mg/kg/day</td>
</tr>
<tr>
<td>N=39 %</td>
<td>23</td>
<td>38</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>26</td>
<td>25</td>
</tr>
<tr>
<td>Somnolence, sedation, lethargy</td>
<td>18</td>
<td>23</td>
</tr>
<tr>
<td>Abnormal echocardiogram</td>
<td>31</td>
<td>15</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3</td>
<td>10</td>
</tr>
<tr>
<td>Constipation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse Reaction</td>
<td>FINTEPLA Dose Group</td>
<td>Combined Placebo Group</td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>---------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td></td>
<td>Study 1</td>
<td>Study 2</td>
</tr>
<tr>
<td></td>
<td>0.2 mg/kg/day</td>
<td>0.7 mg/kg/day</td>
</tr>
<tr>
<td></td>
<td>N=39 %</td>
<td>N=40 %</td>
</tr>
<tr>
<td>Fatigue, malaise, asthenia</td>
<td>15</td>
<td>10</td>
</tr>
<tr>
<td>Ataxia, balance disorder, gait disturbance</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Abnormal behavior</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>Blood pressure increased</td>
<td>13</td>
<td>8</td>
</tr>
<tr>
<td>Drooling, salivary hypersecretion</td>
<td>13</td>
<td>8</td>
</tr>
<tr>
<td>Hypotonia</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>Rash</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Blood prolactin increased</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Chills</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Decreased activity</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Dehydration</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Insomnia</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>15</td>
<td>5</td>
</tr>
<tr>
<td>Stereotypy</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>21</td>
<td>5</td>
</tr>
<tr>
<td>Vomiting</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>Weight decreased</td>
<td>13</td>
<td>5</td>
</tr>
<tr>
<td>Croup</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Ear infection</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>Gastroenteritis</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>Increased heart rate</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Irritability</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Rhinitis</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>Tremor</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Urinary incontinence</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Decreased blood glucose</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Bronchitis</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Contusion</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Eczema</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Enuresis</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Fall</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>Headache</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>Laryngitis</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Negativism</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Status epilepticus</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Viral infection</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

(1) 0.4 mg/kg/day was not an intermediate dose. Patients on the 0.4 mg/kg/day dose were also taking concomitant stiripentol plus clobazam, which increases exposure of FINTEPLA.

(2) Patients in placebo groups from Studies 1 and 2 were pooled.

(3) Consisted of trace and mild mitral regurgitation, and trace aortic regurgitation, which are considered physiologic.
Lennox-Gastaut Syndrome

In the placebo-controlled trial of patients with LGS taking concomitant standard of care AEDs (Study 3), 176 patients were treated with FINTEPLA and 87 patients received placebo [see Clinical Studies (14.2)]. The duration of treatment in this trial was 16 weeks. The mean age was 13.7 years (range 2 to 35 years) and 29% of patients were at least 18 years of age, 45% of patients were female, and 79% were White. All patients were receiving at least one other AED.

The rates of discontinuation as a result of any adverse reaction were 6% and 5% for patients treated with FINTEPLA 0.7 mg/kg/day and 0.2 mg/kg/day, respectively, compared to 1% for patients on placebo. The most frequent adverse reactions leading to discontinuation in the patients treated with any dose of FINTEPLA were seizure (2%) and somnolence (2%).

The common adverse reactions that occurred in patients treated with FINTEPLA (incidence at least 10% and greater than placebo) were diarrhea; decreased appetite; fatigue; somnolence; vomiting.

Table 4 lists the adverse reactions that were reported in 5% or more of patients treated with FINTEPLA and at a rate greater than those on placebo during the titration and maintenance phases of Study 3.

Table 3: Adverse Reactions in 5% or More of Patients Treated with FINTEPLA and Greater Than Placebo in the Placebo-Controlled Trial for Lennox Gastaut Syndrome (Study 3)

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>FINTEPLA Dose Group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Study 3</td>
</tr>
<tr>
<td></td>
<td>0.2 mg/kg/day</td>
</tr>
<tr>
<td></td>
<td>N=89</td>
</tr>
<tr>
<td></td>
<td>%</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>20</td>
</tr>
<tr>
<td>Fatigue, malaise, asthenia</td>
<td>14</td>
</tr>
<tr>
<td>Somnolence, sedation, lethargy</td>
<td>12</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>11</td>
</tr>
<tr>
<td>Constipation</td>
<td>6</td>
</tr>
<tr>
<td>Vomiting</td>
<td>14</td>
</tr>
<tr>
<td>Weight decreased</td>
<td>2</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>8</td>
</tr>
<tr>
<td>Seizure</td>
<td>9</td>
</tr>
<tr>
<td>Irritability</td>
<td>8</td>
</tr>
</tbody>
</table>

Echocardiographic Safety Assessments of Valvular Heart Disease and Pulmonary Arterial Hypertension

Valvular heart disease and pulmonary arterial hypertension were evaluated in the placebo-controlled and open-label extension studies via echocardiography for up to 3 years in duration for 341 DS patients and 263 LGS patients [see Warnings and Precautions (5.1)]. Screening for valvular heart disease assessed for mild or greater aortic regurgitation or moderate or greater
mitral regurgitation, and assessed for additional characteristics of VHD (e.g., valve thickening or restrictive valve motion).

In these clinical studies, two patients with LGS exhibited mild aortic regurgitation (AR) but neither patient had any cardiac signs or symptoms or evidence of valvular structural changes. Neither patient had VHD. The rates of mild AR are consistent with those seen in the screening period prior to treatment (3 patients in LGS and 1 patient in DS clinical trials).

7 DRUG INTERACTIONS

7.1 Effect of Other Drugs on FINTEPLA

Stiripentol Plus Clobazam

Coadministration of FINTEPLA with stiripentol plus clobazam, with or without valproate, increases fenfluramine plasma concentrations [see Clinical Pharmacology (12.3)]. If FINTEPLA is coadministered with stiripentol plus clobazam, the maximum daily dosage of FINTEPLA is 0.2 mg/kg twice daily (maximum daily dosage of 17 mg) [see Dosage and Administration (2.2)].

Strong CYP1A2, CYP2B6, or CYP3A Inducers

Coadministration of FINTEPLA with strong CYP1A2, CYP2B6, or CYP3A inducers will decrease fenfluramine plasma concentrations, which may lower the efficacy of FINTEPLA [see Clinical Pharmacology (12.3)].

It is recommended to avoid coadministration of strong CYP1A2, CYP2B6 or CYP3A inducers. If coadministration of a strong CYP1A2, CYP2B6, or CYP3A inducer with FINTEPLA is necessary, monitor the patient for reduced efficacy and consider increasing the dosage of FINTEPLA as needed; however, do not exceed the maximum daily dosage of FINTEPLA [see Dosage and Administration (2.2)].

If a strong CYP1A2, CYP2B6, or CYP3A inducer is discontinued during maintenance treatment with FINTEPLA, consider gradual reduction in the FINTEPLA dosage to the dose administered prior to initiating the inducer [see Warnings and Precautions (5.6)].

Strong CYP1A2 or CYP2D6 Inhibitors

Coadministration of FINTEPLA with strong CYP1A2 or CYP2D6 inhibitors will increase fenfluramine plasma concentrations [see Clinical Pharmacology (12.3)]. If FINTEPLA is coadministered with strong CYP1A2 or CYP2D6 inhibitors, the maximum daily dosage of FINTEPLA is 20 mg [see Dosage and Administration (2.3)].

If a strong CYP1A2 or CYP2D6 inhibitor is discontinued during maintenance treatment with FINTEPLA, consider gradual increase in the FINTEPLA dosage to the dose recommended without CYP1A2 or CYP2D6 inhibitors; however, do not exceed the maximum daily dosage of FINTEPLA [see Dosage and Administration (2.2)].

If FINTEPLA is coadministered with stiripentol and a strong CYP1A2 or CYP2D6 inhibitor, do not exceed the maximum daily dosage of FINTEPLA of 17 mg [see Dosage and Administration (2.3)].
7.2 Effects of Serotonin Receptor Antagonists

Cyproheptadine and potent 5-HT1A, 5-HT1D, 5-HT2A, and 5-HT2C serotonin receptor antagonists may decrease the efficacy of FINTEPLA. If cyproheptadine or potent 5-HT1A, 5-HT1D, 5-HT2A, or 5-HT2C serotonin receptor antagonists are coadministered with FINTEPLA, patients should be monitored appropriately.

7.3 Serotonergic Drugs

Concomitant administration of FINTEPLA and drugs (e.g., SSRIs, SNRIs, TCAs, MAO inhibitors, trazodone, etc.), over-the-counter medications (e.g., dextromethorphan), or herbal supplements (e.g., St. John’s Wort) that increase serotonin may increase the risk of serotonin syndrome [see Warnings and Precautions (5.7)]. Concomitant use of FINTEPLA is contraindicated within 14 days of taking MAOIs. Use FINTEPLA with caution in patients taking other medications that increase serotonin.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), such as FINTEPLA, during pregnancy. Encourage women who are taking FINTEPLA during pregnancy to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling the toll-free number 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org.

Risk Summary

There are no data on FINTEPLA use in pregnant women. Available data from epidemiologic studies with fenfluramine or dexfenfluramine are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. FINTEPLA can cause decreased appetite and decreased weight [see Warnings and Precautions (5.3)]; monitor for adequate weight gain during pregnancy. In animal studies, administration of fenfluramine throughout organogenesis (rat and rabbit) or throughout gestation and lactation (rat) resulted in adverse effects on development (fetal malformations, embryofetal and offspring mortality and growth impairment) in the presence of maternal toxicity at clinically relevant maternal plasma levels of fenfluramine and its major active metabolite (see Data).

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Data

Animal Data

Oral administration of fenfluramine (0, 5, 10, or 40 mg/kg/day) to pregnant rats during organogenesis resulted in decreased fetal body weights and marked increases in fetal
malformations (external, visceral, and skeletal) at the highest dose tested, which was associated with maternal toxicity. At the no-effect dose (10 mg/kg/day) for adverse effects on embryofetal development in rats, maternal plasma exposures (AUC) of fenfluramine and norfenfluramine (the major metabolite) were approximately 2 and 5 times, respectively, those in humans at the maximum recommended human dose (MRHD) of 26 mg/day.

Oral administration of fenfluramine (0, 5, 10, 15 mg/kg/day) to pregnant rabbits throughout organogenesis resulted in increased embryofetal mortality at all doses and increases in fetal malformations (external and skeletal) at the highest dose tested, which was associated with maternal toxicity. A no-adverse-effect dose for adverse effects on embryofetal development in rabbits was not identified. At the lowest dose tested in rabbits (5 mg/kg/day), maternal plasma exposures of fenfluramine and norfenfluramine were lower than those in humans at the MRHD.

Oral administration of fenfluramine (0, 5, 10, or 40 mg/kg/day) to female rats throughout gestation and lactation resulted in marked increases in stillborn pups and neonatal offspring deaths at the highest dose tested and delayed growth and reflex development during the pre-weaning period at all doses. Maternal body weight gain was decreased at all doses during pregnancy and at the two highest doses during lactation. A no-adverse-effect dose for adverse effects on pre- and postnatal development in rats was not determined. At the lowest dose tested in rats (5 mg/kg/day), maternal plasma exposures of fenfluramine and norfenfluramine were approximately 0.5 and 3 times, respectively, those in humans at the MRHD.

8.2 Lactation

Risk Summary

There are no data on the presence of fenfluramine or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production.

The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for FINTEPLA and any potential adverse effects on the breastfed infant from FINTEPLA or from the underlying maternal condition.

8.3 Females and Males of Reproductive Potential

Infertility

In animal studies, oral administration of fenfluramine resulted in adverse reproductive effects in males and females at clinically relevant doses in the presence of parental toxicity [see Nonclinical Toxicology (13.1)].

8.4 Pediatric Use

The safety and effectiveness of FINTEPLA for the treatment of seizures associated with DS and LGS have been established in patients 2 years of age and older.

Use of FINTEPLA for the treatment of seizures associated with DS in patients 2 years of age and older is supported by two randomized, double-blind, placebo-controlled trials in 202 patients 2 to 18 years of age. Use of FINTEPLA for the treatment of seizures associated with LGS is supported by a randomized, double-blind, placebo-controlled study in 263 patients aged 2 to 35
years, including 187 patients less than 18 years [see Boxed Warning, Warnings and Precautions (5), Adverse Reaction (6.1), and Clinical Studies (14)].

FINTEPLA can cause decreases in appetite and weight. The growth of pediatric patients treated with FINTEPLA should be carefully monitored.

Safety and effectiveness in patients less than 2 years of age have not been established.

Juvenile Animal Data

Oral administration of fenfluramine (0, 3.5, 9, or 20 mg/kg/day) to young rats for 10 weeks starting on postnatal day 7 resulted in reduced body weight and neurobehavioral changes (decreased locomotor activity and learning and memory deficits) at all doses tested. Neurobehavioral effects persisted after dosing was discontinued. Bone size was decreased at the mid and high doses; brain size was decreased at the highest dose. Partial or complete recovery was seen for these endpoints. A no-effect dose for postnatal developmental toxicity was not identified. The lowest dose tested (3.5 mg/kg/day) was associated with plasma fenfluramine exposures (AUC) less than that in humans at the maximum recommended human dose (MRHD) of 26 mg/day and norfenfluramine (metabolite) exposures (AUC) approximately 2 times that in humans at the MRHD.

8.5 Geriatric Use

Clinical studies of FINTEPLA for the treatment of DS or LGS did not include patients 65 years of age and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

8.6 Renal Impairment

In patients with estimated glomerular filtration rate (eGFR) 15 to 29 mL/min/1.73m², do not exceed the maximum daily dosage of FINTEPLA of 20 mg. In patients with eGFR 15 to 29 ml/min/1.73m² and concomitant stiripentol use, do not exceed the maximum daily dosage of FINTEPLA of 17 mg [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)]. FINTEPLA has not been studied in patients with eGFR < 15 mL/min/1.73m².

8.7 Hepatic Impairment

Administration of FINTEPLA to patients with hepatic impairment is not recommended [see Clinical Pharmacology (12.3)].

9 DRUG ABUSE AND DEPENDENCE

9.1 Controlled Substance

FINTEPLA contains fenfluramine, a Schedule IV controlled substance.

10 OVERDOSAGE

Overdose has not been observed in the FINTEPLA clinical trial program. However, overdose of fenfluramine, the active ingredient in FINTEPLA, has been reported at higher doses than those
included in the clinical trial program. Some of the cases were fatal. Events reported after
der overdose include mydriasis, tachycardia, flushing, tremors/twitching/muscle spasms,
agitation/restlessness/anxiety, increased muscle tone/rigor/opisthotonos, respiratory distress or
failure, and seizure. Seizure, coma, and cardiorespiratory arrest were reported in most of the fatal
overdoses.

There is no available specific antidote to the overdose reactions of FINTEPLA. In the event of
overdose, standard medical practice for the management of drug overdosage should be used. An
adequate airway, oxygenation, and ventilation should be ensured; monitoring of cardiac rhythm
and vital sign measurement is recommended. A certified poison control center should be
contacted for updated information on the management of overdose with FINTEPLA.

11 DESCRIPTION

FINTEPLA oral solution contains 2.2 mg/mL fenfluramine, equivalent to 2.5 mg/mL of the
hydrochloride salt.

The active ingredient, fenfluramine hydrochloride, is designated chemically as N-ethyl-α-
methyl-3-(trifluoromethyl)phenethylamine hydrochloride.

The structural formula is:

\[
\begin{align*}
\text{F}\text{3C} & \text{H} \\
& \text{Me} \\
& \text{Me} \\
& \text{N} \text{Me} \text{HCl}
\end{align*}
\]

Fenfluramine hydrochloride is a white to off-white crystalline solid. The pKa of fenfluramine is
10.2.

FINTEPLA is a clear, colorless solution, pH 5.

FINTEPLA contains the following inactive ingredients: cherry flavor, citric acid, ethylparaben
hydroxyethylcellulose, methylparaben, potassium citrate, sucralose, and water.

FINTEPLA contains no ingredient made from gluten-containing grain (wheat, barley, or rye),
and contains not more than 0.1% of carbohydrates, which is solely derived from the cherry
flavor.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The precise mechanism by which fenfluramine exerts its therapeutic effects in the treatment of
seizures associated with Dravet syndrome and Lennox-Gastaut syndrome is unknown.

Fenfluramine and the metabolite, norfenfluramine, exhibit agonist activity at serotonin 5-HT2
receptors. There is an association between serotonergic drugs with 5-HT2B receptor agonist
activity, including fenfluramine and norfenfluramine, and valvular heart disease and pulmonary
arterial hypertension.
12.2 Pharmacodynamics

Cardiac Electrophysiology

At a dose 4 times the maximum recommended dose, FINTEPLA did not prolong the QT interval when tested in an adult population.

12.3 Pharmacokinetics

The pharmacokinetics of fenfluramine and norfenfluramine were studied in healthy subjects, in pediatric patients with DS, and in pediatric and adult patients with LGS. The steady-state systemic exposure (Cmax and AUC) of fenfluramine was slightly greater than dose proportional over the dose range of 13 to 51.8 mg twice-daily fenfluramine (i.e., 1 to 4 times the maximum recommended dose). In pediatric patients with DS who received FINTEPLA 0.7 mg/kg/day, up to a total daily dose of 26 mg fenfluramine, the geometric mean steady-state fenfluramine (coefficient of variation) Cmax was 68.0 (41%) ng/mL and AUC0-24h was 1390 (44%) ng*h/mL.

Absorption

Fenfluramine has a time to maximum plasma concentration (Tmax) of 3 to 5 hours at steady state. The absolute bioavailability of fenfluramine is approximately 68-74%. There was no effect of food on the pharmacokinetics of fenfluramine or norfenfluramine.

Distribution

The geometric mean (CV%) apparent volume of distribution (Vz/F) of fenfluramine is 11.9 (16.5%) L/kg following oral administration of FINTEPLA in healthy subjects. Fenfluramine is 50% bound to human plasma proteins in vitro and binding is independent of drug concentrations.

Elimination

The elimination half-life of fenfluramine was 20 hours and the geometric mean (CV%) clearance (CL/F) was 24.8 (29%) L/h, following oral administration of FINTEPLA in healthy subjects.

Metabolism

Over 75% of fenfluramine is metabolized to norfenfluramine prior to elimination, primarily by CYP1A2, CYP2B6, and CYP2D6. Other CYP enzymes involved to a minor extent are CYP2C9, CYP2C19, and CYP3A4/5. Norfenfluramine is then deaminated and oxidized to form inactive metabolites.

Excretion

Most of an orally administered dose of fenfluramine (greater than 90%) is excreted in the urine as fenfluramine, norfenfluramine, or other metabolites with fenfluramine and norfenfluramine accounting for less than 25% of the total; less than 5% is found in feces.

Specific Populations

The effect of age (range: 2 to 50 years), sex, and race had no clinically meaningful effect on the pharmacokinetics of fenfluramine.

Renal Impairment

In a dedicated clinical study comparing the pharmacokinetics of a single dose of 0.4 mg/kg FINTEPLA in subjects with severe renal impairment (eGFR < 30 mL/min/1.73m² determined by
MDRD) and matched healthy volunteers, $C_{\text{max}}$ and $AUC_{0-\text{inf}}$ of fenfluramine increased by 20% and 88%, respectively, and $C_{\text{max}}$ and $AUC_{0-\text{inf}}$ of norfenfluramine increased by 13% and 21%, respectively in subjects with severe renal impairment [see Use in Specific Populations (8.6)]. FINTEPLA has not been studied in patients with eGFR < 15 mL/min/1.73m² (determined by MDRD). It is not known if fenfluramine or norfenfluramine is dialyzable.

**Drug Interaction Studies**

**Clinical Studies**

**Effect of a single dose of stiripentol, clobazam, and valproic acid combination:**

Coadministration of a single 0.7 mg/kg dose of FINTEPLA, with a single dose of a stiripentol, clobazam, and valproic acid combination in healthy volunteers, increased the $AUC_{0-\text{INF}}$ of fenfluramine by 69% and the $C_{\text{max}}$ by 18%, and decreased the $AUC_{0-72 \text{ hours}}$ of norfenfluramine by 41% and the $C_{\text{max}}$ by 42%, as compared to FINTEPLA administered alone.

**Effect of steady state stiripentol plus clobazam, with or without valproate:**

Fenfluramine pharmacokinetic data were collected from patients after receiving multiple fenfluramine administrations in Study 1 as well as Study 2. Population pharmacokinetic modeling and simulation were used to assess the effect of stiripentol plus clobazam with or without valproate on fenfluramine pharmacokinetics. The effect of stiripentol plus clobazam, with or without valproate, on fenfluramine pharmacokinetics is greater when FINTEPLA is at steady-state than for the first dose of FINTEPLA. At steady state in the patient population, the coadministration of 0.1 mg/kg twice daily (0.2 mg/kg/day), maximum 17 mg/day, of FINTEPLA with stiripentol plus clobazam with or without valproate, is expected to result in a 166% increase in fenfluramine $AUC_{0-24}$ and a 38% decrease in norfenfluramine $AUC_{0-24}$, as compared to 0.2 mg/kg/day, maximum 26 mg/day, FINTEPLA dose administered alone [see Dosage and Administration (2.1, 2.2) and Drug Interactions (7.1)].
Effect of steady state cannabidiol:
Coadministration of a single 0.35 mg/kg dose of FINTEPLA with repeated doses of cannabidiol increased the AUC$_{0-\text{INF}}$ of fenfluramine by 59% and the C$_{\text{max}}$ by 10%, and decreased the AUC$_{0-\text{INF}}$ of norfenfluramine by 22% and the C$_{\text{max}}$ by 33%, as compared to FINTEPLA administered alone. This interaction is not expected to be clinically significant.

Effect of strong CYP1A2 or CYP2D6 inhibitors:
Coadministration of a single 0.4 mg/kg dose of FINTEPLA with rifampin (a CYP1A2, CYP2B6, and CYP3A inducer) at steady state (600 mg once daily) in healthy volunteers decreased the AUC$_{0-\text{INF}}$ of fenfluramine by 58% and the C$_{\text{max}}$ by 40%, and decreased the AUC$_{0-\text{INF}}$ of norfenfluramine by 50%, and increased the C$_{\text{max}}$ of norfenfluramine by 13%, as compared to FINTEPLA administered alone [see Drug Interactions (7.1)].

In Vitro Studies
Fenfluramine is primarily metabolized by CYP1A2, CYP2B6, and CYP2D6 in vitro. Other CYP enzymes involved to a minor extent are CYP2C9, CYP2C19, and CYP3A4/5.

Effect of strong CYP1A2, CYP2B6 or CYP3A inducers:
Coadministration of a single 0.4 mg/kg dose of FINTEPLA with rifampin (a CYP1A2, CYP2B6, and CYP3A inducer) at steady state (600 mg once daily) in healthy volunteers decreased the AUC$_{0-\text{INF}}$ of fenfluramine by 58% and the C$_{\text{max}}$ by 40%, and decreased the AUC$_{0-\text{INF}}$ of norfenfluramine by 50%, and increased the C$_{\text{max}}$ of norfenfluramine by 13%, as compared to FINTEPLA administered alone [see Drug Interactions (7.1)].
13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

Oral administration of fenfluramine to Tg.rasH2 mice (0, 5, 15, 40, or 60 mg/kg/day) for 26 weeks and to male and female rats (0, 1, 2.5, or 8 mg/kg/day) for 89 and 97 weeks, respectively, resulted in no evidence of drug-induced tumors in either species. In rats, plasma exposures (AUC) of fenfluramine and norfenfluramine (the major metabolite) at the highest dose tested were approximately 5 and 11 times, respectively, those in humans at the maximum recommended human dose (MRHD) of 26 mg/day.

Mutagenesis

Fenfluramine was negative in an in vitro bacterial mutation (Ames) assay and an in vivo micronucleus and comet assay in rats.

Impairment of Fertility

Oral administration of fenfluramine (0, 3.5, 8, or 20 mg/kg/day) to male and female rats prior to and throughout mating and continuing in females to day 7 of gestation resulted in a decrease in fertility and increases in abnormal sperm and epithelial vacuolation of the epididymis at the highest dose tested and altered estrous cyclicity, decreased corpora lutea and implantations, and increased embryolethality at the mid and high dose. These doses were associated with parental toxicity. The no-effect doses for adverse effects on fertility and reproductive performance in rats (8 and 3.5 mg/kg/day in males and females, respectively) were associated with plasma fenfluramine exposures (AUC) approximately 3 and 0.6 times, respectively, and norfenfluramine exposures approximately 5 and 3 times, respectively, those in humans at the MRHD.

14 CLINICAL STUDIES

14.1 Dravet Syndrome

The effectiveness of FINTEPLA for the treatment of seizures associated with DS in patients 2 years of age and older was established in two randomized, double-blind, placebo-controlled trials in patients 2 to 18 years of age.

Study 1 (N=117) compared a 0.7 mg/kg/day and a 0.2 mg/kg/day dose of FINTEPLA with placebo in patients who were not receiving stiripentol (NCT02682927 and NCT02826863). Study 2 (N=85) compared a 0.4 mg/kg/day dose of FINTEPLA with placebo in patients who were receiving stiripentol and either clobazam, valproate, or both (NCT02926898). In both studies, patients had a clinical diagnosis of DS and were inadequately controlled on at least one AED or other antiseizure treatment including vagal nerve stimulation or a ketogenic diet. Both trials had a 6-week baseline period, during which patients were required to have a minimum of 6 convulsive seizures while on stable AED therapy. Convulsive seizures included tonic, clonic, generalized tonic-clonic, tonic-atonic, secondarily generalized tonic-clonic, hemiclonic, and focal with observable motor signs. The baseline period was followed by randomization into a 2-week (Study 1) or 3-week (Study 2) titration period and a subsequent 12-week maintenance period, where the dose of FINTEPLA remained stable.
In Study 1, 98% of patients were taking between 1 and 4 concomitant AEDs. The most frequently used concomitant AEDs (in at least 25% of patients), were valproate (61%), clobazam (59%), and topiramate (25%). In Study 2, 100% of patients were taking between 2 and 4 concomitant AEDs. The most frequently used concomitant AEDs (in at least 25% of patients), were stiripentol (100%), clobazam (94%), and valproate (89%).

The primary efficacy endpoint in both studies was the change from baseline in the frequency of convulsive seizures per 28 days during the combined 14-week (Study 1) or 15-week (Study 2) titration and maintenance periods (i.e., treatment period). The median longest interval between convulsive seizures was also assessed.

In Study 1 and Study 2, the reduction in convulsive seizure frequency per 28 days was statistically significantly greater for all dose groups of FINTEPLA compared to placebo (Table 5). A reduction in convulsive seizures was observed within 3 to 4 weeks of starting FINTEPLA, and the effect remained generally consistent over the 14- or 15-week treatment period.

**Table 4:** Change in Convulsive Seizure Frequency During the Treatment Period in Patients with Dravet Syndrome (Study 1 and Study 2)

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>FINTEPLA 0.2 mg/kg/day</th>
<th>FINTEPLA 0.7 mg/kg/day</th>
<th>FINTEPLA 0.4 mg/kg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study 1 N=39</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline Period Median</td>
<td>29.4</td>
<td>18.1</td>
<td>18.7</td>
<td>NA</td>
</tr>
<tr>
<td>% Difference Relative to Placebo*</td>
<td>-31.7%</td>
<td>-70.0%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>p-value compared to placebo</td>
<td>0.043</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study 2 N=42</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline Period Median</td>
<td>11.5</td>
<td>NA</td>
<td>NA</td>
<td>15.0</td>
</tr>
<tr>
<td>% Difference Relative to Placebo*</td>
<td>NA</td>
<td>NA</td>
<td>-59.5%</td>
<td></td>
</tr>
<tr>
<td>p-value compared to placebo</td>
<td>NA</td>
<td>NA</td>
<td>&lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>

*Derived from the primary analysis model
±All 0.4 mg/kg/day patients were also taking concomitant stiripentol, which increases the exposure of FINTEPLA.

**Figure 1** and **Figure 2** display the percentage of patients by category of seizure response from baseline in convulsive seizure frequency (per 28 days) during the treatment period in Study 1 and Study 2, respectively.
Figure 1: Proportion of Patients by Category of Seizure Response for FINTEPLA and Placebo in Patients with Dravet Syndrome (Study 1)

Figure 2: Proportion of Patients by Category of Seizure Response for FINTEPLA and Placebo in Patients with Dravet Syndrome (Study 2)
In Study 1, 3 of 40 (8%) patients in the FINTEPLA 0.7 mg/kg/day group and 3 of 38 (8%) patients in the FINTEPLA 0.2 mg/kg/day group reported no convulsive seizures during the 14-week treatment period, compared to 0 patients in the placebo group. In Study 2, 1 of 43 (2%) patients in the FINTEPLA 0.4 mg/kg/day group reported no convulsive seizures during the 15-week treatment period, compared to 0 patients in the placebo group.

In Study 1 and Study 2, FINTEPLA was associated with a statistically significant longer interval between convulsive seizures compared to placebo (Figure 3).
14.2 Lennox-Gastaut Syndrome

The effectiveness of FINTEPLA for the treatment of seizures associated with LGS in patients 2 years of age and older was established in a randomized, double-blind, placebo-controlled study in 263 patients 2 to 35 years of age (Study 3; NCT03355209).
Study 3 compared a 0.7 mg/kg/day and a 0.2 mg/kg/day dose of FINTEPLA with placebo. Patients had a diagnosis of LGS and were inadequately controlled on at least one AED, without vagal nerve stimulation and/or ketogenic diet. The study had a 4-week baseline period, during which patients were required to have a minimum of 8 drop seizures while on stable AED therapy. Drop seizures were generalized tonic-clonic, secondarily generalized tonic-clonic, tonic, atonic, or tonic-atonic seizures that were confirmed to result in drops. The baseline period was followed by randomization into a 2-week titration period and a subsequent 12-week maintenance period, where the dose of FINTEPLA remained stable.

In Study 3, 99% of patients were taking between 1 and 4 concomitant AEDs. The most frequently used concomitant AEDs (in at least 25% of patients) were clobazam (45%), lamotrigine (34%), and valproate (56%).

The primary efficacy endpoint in Study 3 was the median percent change from baseline in the frequency of drop seizures per 28 days during the combined 14-week titration and maintenance periods (i.e., treatment period). The proportion of patients who achieve improvement (minimally, much, or very much improved) in the Clinical Global Impression of Change (CGI-I) as assessed by Principal Investigator was a secondary endpoint.

In Study 3, the median percent change from baseline (reduction) in the frequency of drop seizures per 28 days was significantly greater for the 0.7 mg/kg/day dose group of FINTEPLA compared with placebo (Table 6). A reduction in drop seizures was observed within 2 weeks of initiating treatment with FINTEPLA, and the effect remained generally consistent over the 14-week treatment period.

The median percent reduction from baseline in drop seizure frequency per 28 days for the lower dose of FINTEPLA (0.2 mg/kg/day) did not reach statistical significance compared to placebo (Table 6).

**Table 5:** Change in Drop Seizure Frequency during the Treatment Period in Patients with Lennox-Gastaut Syndrome (Study 3)

<table>
<thead>
<tr>
<th>Drop Seizure Frequency (per 28 days)</th>
<th>Placebo</th>
<th>FINTEPLA 0.2 mg/kg/day</th>
<th>FINTEPLA 0.7 mg/kg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study 3</td>
<td>N=85*</td>
<td>N=86*</td>
<td>N=83*</td>
</tr>
<tr>
<td>Baseline Period Median Seizure Frequency</td>
<td>55.0</td>
<td>77.8</td>
<td>80.0</td>
</tr>
<tr>
<td>Median Percentage Change from Baseline During Treatment</td>
<td>-8.7%</td>
<td>-13.2%</td>
<td>-23.7%</td>
</tr>
<tr>
<td>p-value compared to placebo</td>
<td>0.1917#</td>
<td>0.0037</td>
<td></td>
</tr>
</tbody>
</table>

*The total number of patients upon which the efficacy analysis was based is less than the total number randomized in the double-blind, placebo-controlled study because patients with missing data were excluded from the efficacy analysis.

# Not statistically significant

Figure 4 displays the percentage of patients by category of reduction from baseline in drop seizure frequency per 28 days during the treatment period in Study 3.
Figure 4: Proportion of Patients by Category of Seizure Response for FINTEPLA and Placebo in Patients with Lennox–Gastaut Syndrome (Study 3)

Numerically greater improvements on the CGI-I by Investigator were observed in patients treated with FINTEPLA compared with placebo.

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

FINTEPLA oral solution is a clear, colorless, cherry flavored liquid containing 2.2 mg/mL fenfluramine and is supplied in a white plastic bottle with a child resistant closure as follows:

- Carton containing one 360 mL bottle (NDC 43376-322-36)
- Carton containing one 30 mL bottle (NDC 43376-322-30)

Before dispensing, the pharmacist will insert a press-in bottle adapter into the dispensing bottle. The pharmacy will provide 3 mL or 6 mL calibrated oral dosing syringes.

16.2 Storage and Handling

Store FINTEPLA at room temperature between 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

Do not refrigerate or freeze. Store the bottle and syringe together.

Discard any unused portion 3 months after first opening the bottle or the “Discard After” date on the bottle, whichever is sooner.
PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).

Administration Information

Advise patients who are prescribed FINTEPLA to use the oral dosing syringes provided by the pharmacy [see Dosage and Administration (2.6) and Instructions for Use]. Instruct patients to discard any unused FINTEPLA 3 months after first opening the bottle or if the “discard after” date on the dispensing bottle has passed, whichever is sooner [see How Supplied/Storage and Handling (16.1), 16.2].

Valvular Heart Disease and Pulmonary Arterial Hypertension

Advise patients that cardiac monitoring must be performed using echocardiography to monitor for serious heart valve changes or high blood pressure in the arteries of the lungs [see Warnings and Precautions (5.1)].

FINTEPLA REMS Program

FINTEPLA is available only through a restricted program called the FINTEPLA REMS program [see Warnings and Precautions (5.2)]. Inform the patient of the following notable requirements:

- Patients must enroll in the program and comply with ongoing echocardiogram monitoring requirements [see Warnings and Precautions (5.1)].

FINTEPLA is only prescribed by certified health care providers and only dispensed from certified pharmacies participating in the program. Therefore, provide patients with the telephone number and website for information on how to obtain the product [see Warnings and Precautions (5.2)].

Decreased Appetite and Decreased Weight

Advise patients that decreased appetite is frequent during treatment with FINTEPLA, which can cause decrease in weight [see Warnings and Precautions (5.3)].

Somnolence, Sedation, and Lethargy

Inform patients that FINTEPLA can cause somnolence, sedation, and lethargy. Caution patients about operating hazardous machinery, including motor vehicles, until they are reasonably certain that FINTEPLA does not affect them adversely (e.g., impair judgment, thinking, or motor skills) [see Warnings and Precautions (5.4)].

Suicidal Thinking and Behavior

Counsel patients, their caregivers, and their families that antiepileptic drugs may increase the risk of suicidal thoughts and behavior and advise them to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts of self-harm. Instruct patients, caregivers, and families to report behaviors of concern immediately to healthcare providers [see Warnings and Precautions (5.5)].

Withdrawal of Antiepileptic Drugs (AEDs)

Advise patients not to discontinue use of FINTEPLA without consulting with their healthcare provider. FINTEPLA should normally be gradually withdrawn to reduce the potential for
increased seizure frequency and status epilepticus [see Dosage and Administration (2.7), Warnings and Precautions (5.6)].

**Serotonin Syndrome**

Inform patients about the risk of serotonin syndrome, which can be life-threatening. Advise patients on the signs and symptoms of serotonin syndrome and that certain over-the-counter medications and herbal supplements can increase this risk [see Warnings and Precautions (5.7)].

**Increase in Blood Pressure**

Inform patients that FINTEPLA can cause an increase in blood pressure [see Warnings and Precautions (5.8)].

**Glaucoma**

Inform patients that FINTEPLA can cause mydriasis and can precipitate angle closure glaucoma. Instruct patients to contact their healthcare provider if they have any acute decreases in visual acuity or ocular pain [see Warnings and Precautions (5.9)].

**Pregnancy Registry**

Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during FINTEPLA therapy. Encourage women who are taking FINTEPLA to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy [see Use in Specific Populations (8.1)].

Marketed by: Zogenix, Inc.
5959 Horton Street, Suite 500, Emeryville CA, 94608